 Daniel Bowles
Concepts (347)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antineoplastic Agents | 30 | 2024 | 2129 | 3.430 |
Why?
| | Salivary Gland Neoplasms | 8 | 2023 | 41 | 2.960 |
Why?
| | Head and Neck Neoplasms | 16 | 2023 | 606 | 2.910 |
Why?
| | Carcinoma, Squamous Cell | 14 | 2019 | 683 | 2.260 |
Why?
| | Protein Kinase Inhibitors | 14 | 2024 | 916 | 2.240 |
Why?
| | Pyridines | 11 | 2024 | 506 | 2.070 |
Why?
| | Thyroid Neoplasms | 9 | 2024 | 343 | 1.920 |
Why?
| | Molecular Targeted Therapy | 7 | 2021 | 411 | 1.720 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 8 | 2023 | 1081 | 1.700 |
Why?
| | Neoplasm Recurrence, Local | 7 | 2023 | 1079 | 1.650 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 14 | 2024 | 1692 | 1.570 |
Why?
| | Neoplasms | 20 | 2024 | 2671 | 1.530 |
Why?
| | Protein-Tyrosine Kinases | 4 | 2021 | 434 | 1.480 |
Why?
| | Anilides | 6 | 2024 | 73 | 1.410 |
Why?
| | Gonanes | 7 | 2016 | 27 | 1.390 |
Why?
| | Lung Neoplasms | 10 | 2023 | 2526 | 1.370 |
Why?
| | Proto-Oncogene Proteins | 6 | 2021 | 648 | 1.350 |
Why?
| | Thyroid Carcinoma, Anaplastic | 3 | 2020 | 34 | 1.310 |
Why?
| | Cetuximab | 7 | 2018 | 98 | 1.300 |
Why?
| | Biomarkers, Tumor | 8 | 2020 | 1276 | 1.270 |
Why?
| | Adenocarcinoma | 7 | 2024 | 940 | 1.250 |
Why?
| | Phosphatidylinositol 3-Kinases | 8 | 2017 | 366 | 0.850 |
Why?
| | Mutation | 13 | 2024 | 3958 | 0.780 |
Why?
| | Carcinoma | 3 | 2019 | 240 | 0.730 |
Why?
| | Drugs, Investigational | 2 | 2011 | 33 | 0.710 |
Why?
| | Phytotherapy | 2 | 2012 | 83 | 0.710 |
Why?
| | Neoplasm Staging | 15 | 2019 | 1389 | 0.700 |
Why?
| | Cisplatin | 6 | 2024 | 320 | 0.700 |
Why?
| | Pyrazoles | 5 | 2023 | 423 | 0.660 |
Why?
| | Disease-Free Survival | 10 | 2017 | 686 | 0.640 |
Why?
| | Neoplasms, Second Primary | 1 | 2021 | 118 | 0.640 |
Why?
| | Antineoplastic Agents, Immunological | 2 | 2018 | 190 | 0.630 |
Why?
| | Papillomaviridae | 4 | 2019 | 125 | 0.630 |
Why?
| | Taxoids | 3 | 2015 | 102 | 0.630 |
Why?
| | Quinolines | 5 | 2024 | 178 | 0.630 |
Why?
| | Hedgehog Proteins | 3 | 2015 | 195 | 0.620 |
Why?
| | Carcinoma, Renal Cell | 3 | 2017 | 217 | 0.610 |
Why?
| | Humans | 89 | 2024 | 137585 | 0.610 |
Why?
| | Drug Resistance, Neoplasm | 8 | 2024 | 801 | 0.580 |
Why?
| | Marijuana Smoking | 2 | 2012 | 252 | 0.580 |
Why?
| | Tumor Suppressor Proteins | 2 | 2018 | 327 | 0.570 |
Why?
| | Pyrimidines | 5 | 2023 | 470 | 0.570 |
Why?
| | Middle Aged | 43 | 2024 | 33479 | 0.550 |
Why?
| | Colorectal Neoplasms | 2 | 2016 | 806 | 0.540 |
Why?
| | Carcinoma, Mucoepidermoid | 1 | 2017 | 16 | 0.540 |
Why?
| | Kidney Neoplasms | 3 | 2017 | 403 | 0.530 |
Why?
| | Aged | 39 | 2024 | 23961 | 0.530 |
Why?
| | Ubiquitin Thiolesterase | 1 | 2017 | 48 | 0.520 |
Why?
| | Carcinoma, Transitional Cell | 4 | 2017 | 71 | 0.510 |
Why?
| | Carcinoma, Ductal | 1 | 2016 | 11 | 0.510 |
Why?
| | Adenoma, Pleomorphic | 1 | 2016 | 11 | 0.510 |
Why?
| | Sulfones | 2 | 2014 | 110 | 0.510 |
Why?
| | Gene Rearrangement | 2 | 2018 | 150 | 0.500 |
Why?
| | Glycine | 2 | 2014 | 176 | 0.500 |
Why?
| | Cannabinoids | 2 | 2024 | 161 | 0.500 |
Why?
| | Maximum Tolerated Dose | 5 | 2017 | 199 | 0.460 |
Why?
| | Enzyme Inhibitors | 3 | 2014 | 840 | 0.430 |
Why?
| | Drug Interactions | 6 | 2017 | 410 | 0.430 |
Why?
| | Melanoma | 1 | 2021 | 760 | 0.430 |
Why?
| | Pyrroles | 1 | 2014 | 213 | 0.420 |
Why?
| | Iodine Radioisotopes | 5 | 2024 | 145 | 0.410 |
Why?
| | Gene Fusion | 3 | 2023 | 27 | 0.410 |
Why?
| | Signal Transduction | 8 | 2018 | 5079 | 0.410 |
Why?
| | Phenylurea Compounds | 4 | 2024 | 97 | 0.410 |
Why?
| | Male | 44 | 2024 | 67762 | 0.400 |
Why?
| | Receptor Protein-Tyrosine Kinases | 2 | 2012 | 234 | 0.400 |
Why?
| | Genetic Variation | 1 | 2018 | 991 | 0.390 |
Why?
| | Lymph Nodes | 4 | 2017 | 491 | 0.390 |
Why?
| | Female | 45 | 2024 | 73304 | 0.380 |
Why?
| | Indazoles | 3 | 2019 | 69 | 0.380 |
Why?
| | Quinazolines | 1 | 2013 | 251 | 0.370 |
Why?
| | Aged, 80 and over | 15 | 2024 | 7635 | 0.370 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 4 | 2017 | 95 | 0.370 |
Why?
| | Treatment Outcome | 15 | 2024 | 10811 | 0.370 |
Why?
| | Antibodies, Monoclonal, Humanized | 4 | 2024 | 804 | 0.360 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2012 | 122 | 0.360 |
Why?
| | Neoplasm Metastasis | 6 | 2021 | 658 | 0.340 |
Why?
| | Proto-Oncogene Proteins c-ret | 4 | 2023 | 36 | 0.330 |
Why?
| | Adult | 26 | 2024 | 37929 | 0.320 |
Why?
| | Prognosis | 9 | 2021 | 4030 | 0.300 |
Why?
| | ErbB Receptors | 4 | 2017 | 614 | 0.290 |
Why?
| | Papillomavirus Infections | 3 | 2022 | 325 | 0.280 |
Why?
| | Pharmacogenomic Variants | 2 | 2018 | 35 | 0.280 |
Why?
| | Nitriles | 2 | 2022 | 172 | 0.270 |
Why?
| | Urologic Neoplasms | 2 | 2017 | 31 | 0.270 |
Why?
| | Carcinoma, Ductal, Breast | 1 | 2007 | 83 | 0.260 |
Why?
| | Platinum | 2 | 2024 | 50 | 0.260 |
Why?
| | Xenograft Model Antitumor Assays | 7 | 2024 | 872 | 0.260 |
Why?
| | Mitoxantrone | 1 | 2006 | 14 | 0.260 |
Why?
| | Enterobacter | 1 | 2006 | 8 | 0.250 |
Why?
| | Tooth Diseases | 1 | 2006 | 13 | 0.250 |
Why?
| | Esophageal and Gastric Varices | 1 | 2006 | 40 | 0.250 |
Why?
| | Enterobacteriaceae Infections | 1 | 2006 | 43 | 0.240 |
Why?
| | Gene Expression Profiling | 5 | 2018 | 1774 | 0.240 |
Why?
| | Salivary Glands | 2 | 2023 | 33 | 0.240 |
Why?
| | Benzamides | 2 | 2019 | 216 | 0.240 |
Why?
| | Oropharyngeal Neoplasms | 2 | 2016 | 63 | 0.240 |
Why?
| | Acute Kidney Injury | 3 | 2018 | 815 | 0.240 |
Why?
| | Animals | 16 | 2024 | 36940 | 0.240 |
Why?
| | Chemoradiotherapy | 4 | 2020 | 225 | 0.230 |
Why?
| | Serotonin 5-HT3 Receptor Antagonists | 1 | 2024 | 5 | 0.230 |
Why?
| | Clinical Trials as Topic | 3 | 2018 | 1050 | 0.230 |
Why?
| | Registries | 2 | 2016 | 2035 | 0.230 |
Why?
| | Proto-Oncogene Proteins B-raf | 2 | 2024 | 224 | 0.230 |
Why?
| | Receptors, Estrogen | 1 | 2007 | 436 | 0.220 |
Why?
| | Antiemetics | 1 | 2024 | 43 | 0.220 |
Why?
| | Immunotherapy | 2 | 2023 | 641 | 0.220 |
Why?
| | Cannabis | 1 | 2011 | 494 | 0.220 |
Why?
| | Urinary Bladder Neoplasms | 2 | 2017 | 252 | 0.210 |
Why?
| | Carcinoma, Adenoid Cystic | 1 | 2023 | 17 | 0.210 |
Why?
| | Combined Modality Therapy | 4 | 2018 | 1236 | 0.210 |
Why?
| | Models, Biological | 3 | 2024 | 1783 | 0.210 |
Why?
| | Gene Expression Regulation, Neoplastic | 3 | 2019 | 1396 | 0.210 |
Why?
| | Liver Cirrhosis | 1 | 2006 | 316 | 0.210 |
Why?
| | Bacteremia | 1 | 2006 | 214 | 0.210 |
Why?
| | Administration, Oral | 3 | 2014 | 816 | 0.210 |
Why?
| | Phenylthiohydantoin | 1 | 2022 | 42 | 0.190 |
Why?
| | Medical Marijuana | 1 | 2024 | 117 | 0.190 |
Why?
| | Survival Rate | 5 | 2021 | 1972 | 0.190 |
Why?
| | Chemotherapy, Adjuvant | 3 | 2017 | 389 | 0.180 |
Why?
| | Drug Evaluation, Preclinical | 2 | 2013 | 184 | 0.180 |
Why?
| | Radiation Pneumonitis | 1 | 2021 | 29 | 0.180 |
Why?
| | Referral and Consultation | 1 | 2007 | 786 | 0.180 |
Why?
| | Survival Analysis | 4 | 2020 | 1325 | 0.180 |
Why?
| | Breast Neoplasms | 2 | 2019 | 2253 | 0.180 |
Why?
| | Carcinoma, Neuroendocrine | 1 | 2021 | 42 | 0.170 |
Why?
| | TOR Serine-Threonine Kinases | 2 | 2016 | 412 | 0.170 |
Why?
| | Adrenal Cortex Neoplasms | 1 | 2021 | 63 | 0.170 |
Why?
| | Adrenocortical Carcinoma | 1 | 2021 | 65 | 0.170 |
Why?
| | Disease Susceptibility | 2 | 2020 | 347 | 0.170 |
Why?
| | Cystectomy | 2 | 2017 | 37 | 0.160 |
Why?
| | Gene Expression | 2 | 2015 | 1502 | 0.160 |
Why?
| | SEER Program | 1 | 2021 | 227 | 0.160 |
Why?
| | Receptors, Nerve Growth Factor | 1 | 2019 | 17 | 0.160 |
Why?
| | Kaplan-Meier Estimate | 3 | 2017 | 889 | 0.160 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2006 | 630 | 0.160 |
Why?
| | DNA Mutational Analysis | 2 | 2018 | 399 | 0.160 |
Why?
| | Tracheal Neoplasms | 1 | 2019 | 9 | 0.160 |
Why?
| | United States | 8 | 2021 | 14841 | 0.160 |
Why?
| | Radiosurgery | 1 | 2022 | 344 | 0.160 |
Why?
| | Lymph Node Excision | 2 | 2017 | 171 | 0.160 |
Why?
| | Positron Emission Tomography Computed Tomography | 1 | 2020 | 98 | 0.150 |
Why?
| | Smad4 Protein | 1 | 2019 | 38 | 0.150 |
Why?
| | Genetic Heterogeneity | 1 | 2019 | 59 | 0.150 |
Why?
| | Benzazepines | 1 | 2018 | 39 | 0.150 |
Why?
| | Prostatic Neoplasms | 1 | 2006 | 1043 | 0.150 |
Why?
| | Alphapapillomavirus | 2 | 2016 | 39 | 0.150 |
Why?
| | Palliative Care | 2 | 2018 | 758 | 0.140 |
Why?
| | Risk | 1 | 2021 | 912 | 0.140 |
Why?
| | Genomics | 3 | 2021 | 795 | 0.140 |
Why?
| | Disease Management | 2 | 2020 | 628 | 0.140 |
Why?
| | Chromosome Aberrations | 1 | 2019 | 156 | 0.140 |
Why?
| | DNA Mismatch Repair | 1 | 2018 | 49 | 0.140 |
Why?
| | Receptor, ErbB-2 | 2 | 2019 | 341 | 0.140 |
Why?
| | Tissue Fixation | 1 | 2017 | 36 | 0.140 |
Why?
| | Paraffin Embedding | 1 | 2017 | 32 | 0.140 |
Why?
| | Oncogenes | 1 | 2018 | 116 | 0.140 |
Why?
| | Erlotinib Hydrochloride | 1 | 2017 | 72 | 0.140 |
Why?
| | Smokers | 1 | 2018 | 145 | 0.140 |
Why?
| | Nasopharyngeal Neoplasms | 1 | 2017 | 21 | 0.140 |
Why?
| | Formaldehyde | 1 | 2017 | 63 | 0.140 |
Why?
| | Gene Deletion | 1 | 2019 | 391 | 0.130 |
Why?
| | Radiotherapy, Intensity-Modulated | 1 | 2018 | 142 | 0.130 |
Why?
| | Health Services Needs and Demand | 1 | 2019 | 273 | 0.130 |
Why?
| | DNA, Neoplasm | 1 | 2017 | 164 | 0.130 |
Why?
| | Neoplasm Grading | 1 | 2018 | 307 | 0.130 |
Why?
| | Induction Chemotherapy | 1 | 2017 | 76 | 0.130 |
Why?
| | Gene Frequency | 1 | 2018 | 521 | 0.130 |
Why?
| | Chemoradiotherapy, Adjuvant | 1 | 2016 | 43 | 0.130 |
Why?
| | Hospice and Palliative Care Nursing | 1 | 2018 | 75 | 0.130 |
Why?
| | Salivary Ducts | 1 | 2016 | 3 | 0.130 |
Why?
| | Laryngeal Neoplasms | 1 | 2016 | 39 | 0.130 |
Why?
| | Patient Navigation | 1 | 2018 | 81 | 0.130 |
Why?
| | Carboplatin | 1 | 2016 | 144 | 0.130 |
Why?
| | Muscle, Smooth | 1 | 2017 | 155 | 0.130 |
Why?
| | Nomograms | 1 | 2016 | 54 | 0.120 |
Why?
| | Prospective Studies | 7 | 2024 | 7604 | 0.120 |
Why?
| | Database Management Systems | 1 | 2016 | 51 | 0.120 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2017 | 2057 | 0.120 |
Why?
| | Young Adult | 5 | 2021 | 13209 | 0.120 |
Why?
| | Disease Progression | 4 | 2018 | 2757 | 0.120 |
Why?
| | Computational Biology | 2 | 2018 | 644 | 0.120 |
Why?
| | Population Surveillance | 1 | 2019 | 482 | 0.120 |
Why?
| | Retrospective Studies | 8 | 2021 | 15657 | 0.120 |
Why?
| | Angiopoietin-1 | 1 | 2015 | 11 | 0.120 |
Why?
| | Angiopoietin-2 | 1 | 2015 | 16 | 0.120 |
Why?
| | Radiotherapy | 1 | 2016 | 201 | 0.120 |
Why?
| | Incidence | 2 | 2019 | 2804 | 0.120 |
Why?
| | Bone Neoplasms | 1 | 2017 | 247 | 0.120 |
Why?
| | Zinc Finger Protein GLI1 | 1 | 2014 | 25 | 0.120 |
Why?
| | Genetic Testing | 1 | 2018 | 460 | 0.110 |
Why?
| | Retreatment | 1 | 2014 | 72 | 0.110 |
Why?
| | Hospice Care | 1 | 2018 | 202 | 0.110 |
Why?
| | Piperazines | 2 | 2018 | 350 | 0.110 |
Why?
| | Response Evaluation Criteria in Solid Tumors | 1 | 2014 | 18 | 0.110 |
Why?
| | Neoplasms, Unknown Primary | 1 | 2014 | 19 | 0.110 |
Why?
| | Paclitaxel | 1 | 2015 | 230 | 0.110 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2016 | 437 | 0.110 |
Why?
| | Neoplastic Stem Cells | 1 | 2018 | 399 | 0.110 |
Why?
| | Patient Satisfaction | 1 | 2018 | 660 | 0.100 |
Why?
| | Sulfonamides | 1 | 2017 | 513 | 0.100 |
Why?
| | Proportional Hazards Models | 4 | 2017 | 1266 | 0.100 |
Why?
| | Veratrum Alkaloids | 1 | 2013 | 19 | 0.100 |
Why?
| | Promoter Regions, Genetic | 1 | 2018 | 1250 | 0.100 |
Why?
| | ras Proteins | 1 | 2014 | 153 | 0.100 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2017 | 539 | 0.100 |
Why?
| | Pilot Projects | 2 | 2015 | 1710 | 0.100 |
Why?
| | Cell Cycle Proteins | 2 | 2014 | 617 | 0.100 |
Why?
| | PTEN Phosphohydrolase | 1 | 2014 | 167 | 0.100 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2014 | 267 | 0.100 |
Why?
| | Imatinib Mesylate | 1 | 2012 | 79 | 0.100 |
Why?
| | Dasatinib | 1 | 2012 | 54 | 0.100 |
Why?
| | Recombinant Fusion Proteins | 1 | 2015 | 665 | 0.100 |
Why?
| | Risk Assessment | 2 | 2019 | 3457 | 0.100 |
Why?
| | Thiazoles | 1 | 2012 | 123 | 0.090 |
Why?
| | Aniline Compounds | 1 | 2012 | 102 | 0.090 |
Why?
| | Hematopoietic Stem Cells | 1 | 2015 | 406 | 0.090 |
Why?
| | Biomarkers | 3 | 2018 | 4149 | 0.090 |
Why?
| | Proto-Oncogene Proteins c-met | 1 | 2012 | 75 | 0.090 |
Why?
| | Biological Availability | 1 | 2011 | 148 | 0.090 |
Why?
| | Mice | 7 | 2024 | 17787 | 0.090 |
Why?
| | Imidazoles | 1 | 2012 | 238 | 0.090 |
Why?
| | Carcinoma, Basal Cell | 1 | 2012 | 75 | 0.090 |
Why?
| | Smoking | 1 | 2019 | 1627 | 0.090 |
Why?
| | Phosphatidylinositol 3-Kinase | 1 | 2011 | 26 | 0.090 |
Why?
| | Propensity Score | 3 | 2017 | 294 | 0.090 |
Why?
| | Adolescent | 5 | 2022 | 21513 | 0.090 |
Why?
| | Evidence-Based Medicine | 2 | 2012 | 740 | 0.090 |
Why?
| | Vascular Endothelial Growth Factor A | 2 | 2024 | 545 | 0.090 |
Why?
| | Tumor Microenvironment | 1 | 2015 | 674 | 0.090 |
Why?
| | Cell Line, Tumor | 4 | 2024 | 3412 | 0.080 |
Why?
| | Algorithms | 1 | 2018 | 1704 | 0.080 |
Why?
| | Phenotype | 1 | 2018 | 3196 | 0.080 |
Why?
| | Genetic Predisposition to Disease | 1 | 2018 | 2426 | 0.080 |
Why?
| | Kidney | 1 | 2017 | 1468 | 0.080 |
Why?
| | Adaptation, Psychological | 1 | 2014 | 655 | 0.080 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 2 | 2024 | 108 | 0.080 |
Why?
| | Multivariate Analysis | 3 | 2017 | 1509 | 0.080 |
Why?
| | Brain Neoplasms | 1 | 2018 | 1238 | 0.080 |
Why?
| | Axilla | 1 | 2007 | 47 | 0.070 |
Why?
| | Cohort Studies | 4 | 2022 | 5742 | 0.070 |
Why?
| | Neoadjuvant Therapy | 2 | 2022 | 404 | 0.070 |
Why?
| | Clinical Trials, Phase I as Topic | 2 | 2019 | 50 | 0.070 |
Why?
| | Sentinel Lymph Node Biopsy | 1 | 2007 | 115 | 0.070 |
Why?
| | RNA, Messenger | 1 | 2014 | 2833 | 0.060 |
Why?
| | Mastectomy | 1 | 2007 | 137 | 0.060 |
Why?
| | Caregivers | 1 | 2014 | 877 | 0.060 |
Why?
| | Transcription Factors | 1 | 2014 | 1719 | 0.060 |
Why?
| | Ligation | 1 | 2006 | 92 | 0.060 |
Why?
| | Pain | 1 | 2011 | 756 | 0.060 |
Why?
| | Stress, Psychological | 1 | 2014 | 1100 | 0.060 |
Why?
| | Creatinine | 2 | 2018 | 499 | 0.060 |
Why?
| | Fatal Outcome | 1 | 2006 | 303 | 0.060 |
Why?
| | Receptors, Progesterone | 1 | 2007 | 350 | 0.060 |
Why?
| | Lymphatic Metastasis | 2 | 2017 | 352 | 0.060 |
Why?
| | Neoplasm Invasiveness | 2 | 2017 | 510 | 0.060 |
Why?
| | Granisetron | 1 | 2024 | 6 | 0.060 |
Why?
| | Double-Blind Method | 2 | 2021 | 1993 | 0.060 |
Why?
| | Quinuclidines | 1 | 2024 | 9 | 0.060 |
Why?
| | Ondansetron | 1 | 2024 | 16 | 0.060 |
Why?
| | Gastrointestinal Hemorrhage | 1 | 2006 | 132 | 0.060 |
Why?
| | Isoquinolines | 1 | 2024 | 43 | 0.060 |
Why?
| | Risk Factors | 1 | 2019 | 10388 | 0.060 |
Why?
| | Skin Neoplasms | 1 | 2012 | 855 | 0.060 |
Why?
| | Neoplasm Proteins | 1 | 2007 | 434 | 0.050 |
Why?
| | Glomerular Filtration Rate | 2 | 2018 | 746 | 0.050 |
Why?
| | Demography | 2 | 2015 | 291 | 0.050 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 1 | 2023 | 86 | 0.050 |
Why?
| | Benzimidazoles | 1 | 2024 | 170 | 0.050 |
Why?
| | Recurrence | 2 | 2018 | 1060 | 0.050 |
Why?
| | Databases, Factual | 2 | 2019 | 1357 | 0.050 |
Why?
| | Four-Dimensional Computed Tomography | 1 | 2021 | 30 | 0.050 |
Why?
| | Androgen Antagonists | 1 | 2022 | 82 | 0.050 |
Why?
| | Quality of Life | 1 | 2013 | 2892 | 0.040 |
Why?
| | Immunohistochemistry | 2 | 2018 | 1738 | 0.040 |
Why?
| | Pulmonary Ventilation | 1 | 2021 | 79 | 0.040 |
Why?
| | Receptors, Androgen | 1 | 2022 | 150 | 0.040 |
Why?
| | Radiotherapy Planning, Computer-Assisted | 1 | 2021 | 130 | 0.040 |
Why?
| | Receptor, trkA | 1 | 2019 | 18 | 0.040 |
Why?
| | Receptor, trkC | 1 | 2019 | 11 | 0.040 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2019 | 76 | 0.040 |
Why?
| | Receptor, trkB | 1 | 2019 | 33 | 0.040 |
Why?
| | Trastuzumab | 1 | 2019 | 96 | 0.040 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2020 | 171 | 0.040 |
Why?
| | Radiotherapy, Image-Guided | 1 | 2018 | 35 | 0.040 |
Why?
| | Phthalazines | 1 | 2018 | 45 | 0.040 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2019 | 317 | 0.030 |
Why?
| | Organic Cation Transporter 2 | 1 | 2017 | 8 | 0.030 |
Why?
| | Glutathione S-Transferase pi | 1 | 2017 | 11 | 0.030 |
Why?
| | Multidrug Resistance-Associated Proteins | 1 | 2017 | 38 | 0.030 |
Why?
| | Retroperitoneal Space | 1 | 2017 | 20 | 0.030 |
Why?
| | Organic Cation Transport Proteins | 1 | 2017 | 26 | 0.030 |
Why?
| | Urinary Diversion | 1 | 2017 | 12 | 0.030 |
Why?
| | National Cancer Institute (U.S.) | 1 | 2017 | 49 | 0.030 |
Why?
| | Membrane Glycoproteins | 1 | 2019 | 500 | 0.030 |
Why?
| | Social Work | 1 | 2018 | 85 | 0.030 |
Why?
| | Tumor Cells, Cultured | 1 | 2019 | 955 | 0.030 |
Why?
| | Margins of Excision | 1 | 2017 | 50 | 0.030 |
Why?
| | Laryngectomy | 1 | 2016 | 19 | 0.030 |
Why?
| | Immunophenotyping | 1 | 2018 | 318 | 0.030 |
Why?
| | Hospitals, Veterans | 1 | 2018 | 252 | 0.030 |
Why?
| | Oncologists | 1 | 2017 | 38 | 0.030 |
Why?
| | Kidney Function Tests | 1 | 2017 | 160 | 0.030 |
Why?
| | Pelvis | 1 | 2017 | 102 | 0.030 |
Why?
| | Viral Core Proteins | 1 | 2016 | 18 | 0.030 |
Why?
| | Carcinogenesis | 1 | 2018 | 217 | 0.030 |
Why?
| | Cation Transport Proteins | 1 | 2017 | 134 | 0.030 |
Why?
| | Disease Models, Animal | 2 | 2018 | 4295 | 0.030 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2016 | 220 | 0.030 |
Why?
| | Heart | 1 | 2020 | 655 | 0.030 |
Why?
| | Regression Analysis | 1 | 2018 | 1024 | 0.030 |
Why?
| | Internationality | 1 | 2016 | 155 | 0.030 |
Why?
| | Random Allocation | 1 | 2016 | 353 | 0.030 |
Why?
| | Anti-Bacterial Agents | 1 | 2006 | 1809 | 0.030 |
Why?
| | Antibodies, Neoplasm | 1 | 2015 | 34 | 0.030 |
Why?
| | Robotic Surgical Procedures | 1 | 2017 | 130 | 0.030 |
Why?
| | Biopsy, Large-Core Needle | 1 | 2014 | 14 | 0.030 |
Why?
| | Myocardium | 1 | 2020 | 1002 | 0.030 |
Why?
| | Analysis of Variance | 1 | 2017 | 1316 | 0.030 |
Why?
| | Bone Marrow | 1 | 2015 | 286 | 0.030 |
Why?
| | Receptor, Notch2 | 1 | 2013 | 15 | 0.030 |
Why?
| | Receptor Cross-Talk | 1 | 2013 | 21 | 0.030 |
Why?
| | Receptor, Notch1 | 1 | 2013 | 64 | 0.020 |
Why?
| | Metabolic Clearance Rate | 1 | 2012 | 115 | 0.020 |
Why?
| | Pandemics | 1 | 2021 | 1639 | 0.020 |
Why?
| | Gene Silencing | 1 | 2013 | 195 | 0.020 |
Why?
| | Psychiatric Status Rating Scales | 1 | 2014 | 547 | 0.020 |
Why?
| | Needs Assessment | 1 | 2014 | 376 | 0.020 |
Why?
| | Transcriptome | 1 | 2018 | 971 | 0.020 |
Why?
| | Nausea | 1 | 2012 | 111 | 0.020 |
Why?
| | Logistic Models | 1 | 2017 | 2074 | 0.020 |
Why?
| | Area Under Curve | 1 | 2012 | 314 | 0.020 |
Why?
| | Vomiting | 1 | 2012 | 130 | 0.020 |
Why?
| | Mice, Nude | 1 | 2013 | 698 | 0.020 |
Why?
| | Diarrhea | 1 | 2012 | 184 | 0.020 |
Why?
| | Blotting, Western | 1 | 2013 | 1226 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2012 | 786 | 0.020 |
Why?
| | Fatigue | 1 | 2012 | 329 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2017 | 2475 | 0.020 |
Why?
| | Time Factors | 1 | 2019 | 6828 | 0.020 |
Why?
| | Lung | 1 | 2021 | 4060 | 0.020 |
Why?
| | Age Factors | 1 | 2016 | 3295 | 0.020 |
Why?
| | Colorado | 1 | 2018 | 4565 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2016 | 5131 | 0.020 |
Why?
| | Cytokines | 1 | 2015 | 2085 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2018 | 5778 | 0.010 |
Why?
| | Cross-Sectional Studies | 1 | 2014 | 5472 | 0.010 |
Why?
|
|
Bowles's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|